Novo Nordisk Gets CDSCO Panel Nod to Study Cagrilintide plus semaglutide

This came after Novo Nordisk presented Phase II clinical study protocol No. NN9388-7700, version 1.0, dated 25 September 2023.

Cagrilintide/semaglutide is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It is injected once a week and is being tested for type 2 diabetes and obesity.

Cagrilintide is a long-acting amylin analog under investigation for weight management. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus, increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying.

At the recent SEC meeting for endocrinology and metabolism held on June 19, 2024, the expert panel reviewed the Phase II clinical study protocol No. NN9388-7700 version No. 1.0 dated 25 September 2023, presented by the drug major Novo Nordisk.

After detailed deliberation, the committee recommended the grant of permission to conduct the trial with the condition that the firm should include the nephrologists as principal investigators (PI) or co-principal investigators (Co-PI) from the same site or institute.

Also Read:Eli Lilly Company Gets CDSCO Panel Nod To Import, Market Antidiabetic drug Tirzepatide for chronic weight management